Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.
about
Function, regulation and pathological roles of the Gab/DOS docking proteinsGermline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotypeDiversity and functional consequences of germline and somatic PTPN11 mutations in human disease.Constitutively active SHP2 cooperates with HoxA10 overexpression to induce acute myeloid leukemiaLeukemia-associated, constitutively active mutants of SHP2 protein tyrosine phosphatase inhibit NF1 transcriptional activation by the interferon consensus sequence binding proteinRASopathies: unraveling mechanisms with animal modelsGAB2--a scaffolding protein in cancerStructure and function of Gab2 and its role in cancer (Review)Structural and Mechanistic Insights into LEOPARD Syndrome-Associated SHP2 MutationsThe tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancersOrder and disorder in large multi-site docking proteins of the Gab family--implications for signalling complex formation and inhibitor design strategiesRAS diseases in childrenGermline KRAS mutations cause Noonan syndromeDifferential biological activity of disease-associated JAK2 mutantsProtein tyrosine phosphatases in the JAK/STAT pathwayIdentification of PTPsigma as an autophagic phosphatase.A Src family kinase-Shp2 axis controls RUNX1 activity in megakaryocyte and T-lymphocyte differentiation.Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation.Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrumMutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis.SHP2E76K mutant promotes lung tumorigenesis in transgenic micePZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice.Cellular adhesion gene SELP is associated with rheumatoid arthritis and displays differential allelic expression.Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling.Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesisLyn- and PLC-beta3-dependent regulation of SHP-1 phosphorylation controls Stat5 activity and myelomonocytic leukemia-like disease.Critical role of Shp2 in tumor growth involving regulation of c-MycActivating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorderTargeting protein tyrosine phosphatases for anticancer drug discovery.Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool.Germline PTPN11 and somatic PIK3CA variant in a boy with megalencephaly-capillary malformation syndrome (MCAP)--pure coincidence?Protein Tyrosine Phosphatase SHP-2 (PTPN11) in Hematopoiesis and Leukemogenesis.A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells.Role of intracellular tyrosines in activating KIT-induced myeloproliferative diseaseNon-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.Molecular targets for the treatment of juvenile myelomonocytic leukemia.
P2860
Q21245511-153F27A8-D730-45B7-85C6-FAFBB8AF3FCBQ24293473-72ADA44C-E89C-4A16-8457-FC2FC92B81E5Q24540529-6349087A-7302-46CE-A822-527A971EB38CQ24646924-9FBD1EC7-135F-44D3-A3A0-BACFD45AF458Q24670487-59C94ED3-4A36-4640-A40E-A41632B75A42Q26800379-5349E95B-1AD9-4F0F-B907-ACBFBE6A9A8DQ26823140-03A7FD13-4C08-4B5D-9F7D-C2098CD1D687Q26825507-F854F76D-20A5-4F2C-9DC1-EC372AC016DDQ27676674-D57D5EA2-11C2-4F5A-A837-A17A34908A11Q28115840-BC1D7CB6-C33F-4D71-BEC7-87DFDA349A0FQ28248627-AC11EEE0-EC4D-491B-A3A3-ED1EC846762DQ28252058-4535EAF6-041B-41FC-8795-5507B346EA04Q28297024-94479F45-0B03-4D9E-99C0-6E6B7CBDF487Q28508045-4DEE0FF9-1686-44B2-8A9D-70CCBF7F59E9Q28646447-3D91C466-5AC9-479B-B48E-A3D794A1C3BEQ30498183-6FB2BEC6-4269-4346-BF59-6139EFFB21E5Q32884462-BD2E7674-C321-4A41-B8D0-D0B7B1452F0AQ33568776-E3FE5082-5327-449D-BF12-6AC4FB480BF6Q33637874-21FC742C-D0B8-4C2E-A90D-2D40D4ACA5CFQ33722741-B7A80883-BBCE-42CE-BA25-6DBE1ACE9CB6Q33774488-026D09A9-785E-42A2-B489-779121943A43Q33792502-B09EF110-FD6B-408C-8E77-1B9490104174Q34009953-AD7A7B4D-34D3-4CD5-97FC-9B02CB7E0B62Q34056454-CABC955E-882B-4145-BD59-31E9E8364E11Q34078388-4ED1D6F6-3754-456F-9C9D-6C51174003A9Q34103614-F1873389-3C69-4475-83D5-95C8340AF36FQ34130332-DC3F3CEA-ADAC-4582-9D73-6539C5A859F8Q34399676-04CED0BD-338B-4642-948B-2D2CF6B55FFEQ34503441-205F103E-AFA0-4F90-BC27-84B48BD491EFQ34541593-5108424D-C691-42AF-AE50-B41DBC4DEE21Q34713949-226AF199-0CDE-4B82-9E24-757D98DB4A15Q34722748-D6F5A81D-5EDD-4E5C-BB71-F4FFFB3206C1Q34789961-A645B7DC-C65C-47E7-8B51-01229814C986Q35029942-A7169978-46F9-4D21-A018-0909F2250375Q35079964-C75A7736-A257-400B-A965-658036CD4A48Q35101627-80D54844-8EF9-4B57-8EAA-5E178C489A18Q35164251-8B5C500C-6CD9-445C-B5AA-DACA173ACF84Q35230318-A98D24A0-4E42-4374-9CA7-881A4FDF2798Q35237519-BC46CDF5-7E52-4A1E-AF41-ACADE81D3F4DQ35579349-78D968E9-FC46-4F2F-B617-B45896538079
P2860
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Prognostic, therapeutic, and m ...... ed by Shp2 (PTPN11) mutations.
@en
Prognostic, therapeutic, and m ...... ed by Shp2 (PTPN11) mutations.
@nl
type
label
Prognostic, therapeutic, and m ...... ed by Shp2 (PTPN11) mutations.
@en
Prognostic, therapeutic, and m ...... ed by Shp2 (PTPN11) mutations.
@nl
prefLabel
Prognostic, therapeutic, and m ...... ed by Shp2 (PTPN11) mutations.
@en
Prognostic, therapeutic, and m ...... ed by Shp2 (PTPN11) mutations.
@nl
P2093
P1433
P1476
Prognostic, therapeutic, and m ...... ked by Shp2 (PTPN11) mutations
@en
P2093
Benjamin G Neel
Charles R Dearolf
Christina Boulton
D Gary Gilliland
Gordon Chan
Heike Keilhack
Hirokazu Shigematsu
Jeffery L Kutok
Kelly Morgan
Koichi Akashi
P304
P356
10.1016/J.CCR.2005.01.010
P50
P577
2005-02-01T00:00:00Z